Abstract
In a pilot study, proglumide, a cholecystokinin receptor antagonist, was administered to 8 patients affected from Huntington's chorea under long-term haloperidol treatment. The effectiveness of haloperidol on chronic symptomatology was reduced by the concomitant administration of proglumide; the latter drug, when administered alone, did not modify the severity of chorea compared to placebo. Possible explanations of these results are discussed, stressing the modulatory role of CCK not only on the dopaminergic, but also on the GABAergic system.
Publication types
-
Clinical Trial
-
Comparative Study
-
Controlled Clinical Trial
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antipsychotic Agents / antagonists & inhibitors
-
Antipsychotic Agents / therapeutic use*
-
Drug Therapy, Combination
-
Female
-
Haloperidol / antagonists & inhibitors
-
Haloperidol / therapeutic use*
-
Humans
-
Huntington Disease / drug therapy*
-
Huntington Disease / physiopathology
-
Male
-
Middle Aged
-
Pilot Projects
-
Proglumide / therapeutic use*
-
Receptors, Cholecystokinin / antagonists & inhibitors*
-
Severity of Illness Index
Substances
-
Antipsychotic Agents
-
Receptors, Cholecystokinin
-
Proglumide
-
Haloperidol